Cholesterol Drug Zocor Can Increase Risk of Muscle Damage

more+
less-

Simvastatin (marketed as Zocor; also an ingredient in Vytorin and Simcor) is a cholesterol-lowering drug. Merck obtained approval by the FDA in 1991 and it was their largest selling drug prior to the loss of patent protection in early 2006. Zocor was also the second largest selling cholesterol-lowering drug in the world. Merck recorded $4.3 billion in sales for Zocor in 2005. Generic sales began in June 2006. The FDA estimates that over 2 million people were prescribed simvastatin 80 mg in 2010.

A new study shows that 80 mg doses of simvastatin can increase the risk of muscle damage.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robert Kraft, Kraft & Associates | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »